舒他西林治疗尿路感染的临床评价

[Clinical evaluation of sultamicillin in the treatment of urinary tract infections].

作者信息

Fukatsu H, Noonmura H, Miyagawa Y, Waki M, Hatano Y, Hiraiwa S, Muramatsu T, Yamada Y, Segawa A

机构信息

Department of Urology, Aichi Medical University.

出版信息

Hinyokika Kiyo. 1990 Jul;36(7):861-7.

PMID:2239586

Abstract

Sultamicillin, a new semisynthetic oral beta-lactam antibiotic, was evaluated for its antibacteria susceptibility and clinical efficacy against urinary tract infection (UTI), and the following results were obtained. The sensitivity of sultamicillin (SBTPC) on 518 strains of clinical isolates from the urine were tested and compared to ampicillin (ABPC). S. aureus, S. epidermidis, Enterococcus sp., Streptococcus sp., E. coli, K. pneumoniae, K. oxytoca, P. mirabilis, M. morganii and Acinetobacter sp. showed high sensitivity to SBTPC. The antibacterial activity of SBTPC was superior to that of ABPC in most strains and especially more superior in beta-lactamase producing strains. The clinical effectiveness rate on a total of 15 patients with acute uncomplicated cystitis was 93.3% and the eradication rate of causative organisms was 93.3%. On 15 patients with chronic complicated UTI, the clinical effectiveness rate was 73.3% and eradication rate was 76.5%. Side effects (diarrhea) were observed in 3 cases, but this symptom was not severe and soon disappeared. Abnormal laboratory data due to the drug were not observed.

摘要

舒他西林是一种新型半合成口服β-内酰胺类抗生素，对其针对尿路感染（UTI）的抗菌敏感性及临床疗效进行了评估，结果如下。检测了舒他西林（SBTPC）对518株尿液临床分离菌株的敏感性，并与氨苄西林（ABPC）进行比较。金黄色葡萄球菌、表皮葡萄球菌、肠球菌属、链球菌属、大肠杆菌、肺炎克雷伯菌、产酸克雷伯菌、奇异变形杆菌、摩根摩根菌和不动杆菌属对SBTPC表现出高敏感性。在大多数菌株中，SBTPC的抗菌活性优于ABPC，在产β-内酰胺酶的菌株中尤其更具优势。15例急性单纯性膀胱炎患者的临床有效率为93.3%，病原菌根除率为93.3%。15例慢性复杂性UTI患者的临床有效率为73.3%，根除率为76.5%。3例出现副作用（腹泻），但该症状不严重且很快消失。未观察到因药物导致的实验室数据异常。